Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Perjeta Approved for Certain Type of Early BC

Genentech news release; 2017 Dec 20

The FDA has approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment for a certain type of early breast cancer.

Indications: Perjeta is a HER2/neu receptor antagonist indicated for use in combination with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.

Dosage and administration: Administer by intravenous infusion postoperatively every 3 weeks for a total of 1 year (up to 18 cycles).

Efficacy and safety: Approval is based on results of a phase 3 study showing that the combination significantly reduced the risk of invasive breast cancer recurrence or death by 18% vs trastuzumab and chemotherapy alone.

Side effects/risks: The most common adverse reactions are diarrhea, nausea, alopecia, fatigue, peripheral neuropathy, and vomiting.

Citation:

FDA Approves Genentech’s Perjeta (pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer [news release]. South San Francisco, CA: Genentech, Inc. December 20, 2017. https://www.businesswire.com/news/home/20171220006056/en/FDA-Approves-Ge.... Accessed December 31, 2017.

Perjeta [package insert]. South San Francisco, CA: Genentech, Inc., 2017. https://www.gene.com/download/pdf/perjeta_prescribing.pdf. Accessed December 31, 2017.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Must Reads in Breast Cancer

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Advanced age not linked with risk from nipple-sparing mastectomy, Cox S et al. and Bartholomew AJ et al. Session SF310 ACS Clinical Congress 2018

Avoiding topical agents prior to RT may be unnecessary, Baumann BC et al. JAMA Oncol. 2018 Oct 18. doi: 10.1001/jamaoncol.2018.4292

Men with MBC have a similar prognosis compared with women, Sirieix et al. ESMO 2018, Abstract 294PD; Reinisch et al. ESMO 2018, Abstract 273PD